140 related articles for article (PubMed ID: 347106)
21. In vivo skin test in carcinoma bladder.
Gupta NP; Rajagopal V; Malaviya AN; Singh SM
Indian J Cancer; 1984 Nov-1985 Jan; 21(5-6):163-5. PubMed ID: 6545227
[No Abstract] [Full Text] [Related]
22. Prognostic value of host immunocompetence in urologic cancer patients.
Catalona WJ; Smolev JK; Harty JI
J Urol; 1975 Dec; 114(6):922-6. PubMed ID: 1195475
[TBL] [Abstract][Full Text] [Related]
23. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
24. Modulating the immune response to Bacillus Calmette-Guérin (BCG): a novel way to increase the immunotherapeutic effect of BCG for treatment of bladder cancer?
Sapre N; Corcoran NM
BJU Int; 2013 Oct; 112(6):852-3. PubMed ID: 24028766
[No Abstract] [Full Text] [Related]
25. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
26. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
27. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder.
Rosevear HM; Lightfoot AJ; O'Donnell MA; Griffith TS
Cancer Metastasis Rev; 2009 Dec; 28(3-4):345-53. PubMed ID: 19967427
[TBL] [Abstract][Full Text] [Related]
28. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
[TBL] [Abstract][Full Text] [Related]
29. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
30. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
31. Levamisole versus placebo as an adjunct to primary therapy of laryngopharyngeal epidermoid carcinoma. Evaluation of the immune status.
Mussche RA; Plum J; de Smedt M; Kluyskens P
Acta Otorhinolaryngol Belg; 1977; 31(6):566-77. PubMed ID: 339662
[TBL] [Abstract][Full Text] [Related]
32. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
[TBL] [Abstract][Full Text] [Related]
33. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Morales A; Eidinger D; Bruce AW
J Urol; 1976 Aug; 116(2):180-3. PubMed ID: 820877
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure.
McKiernan JM; Holder DD; Ghandour RA; Barlow LJ; Ahn JJ; Kates M; Badalato GM; Roychoudhury A; Decastro GJ; Benson MC
J Urol; 2014 Dec; 192(6):1633-8. PubMed ID: 24996128
[TBL] [Abstract][Full Text] [Related]
35. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
36. Preliminary results of combined surgery and adjuvant Bacillus Calmette-Guérin plus levamisole treatment of resectable lung cancer.
Wright PW; Hill LD; Peterson AV; Pinkham R; Johnson L; Ivey T; Bernstein I; Bagley C; Anderson R
Cancer Treat Rep; 1978 Nov; 62(11):1671-5. PubMed ID: 215304
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant therapy with levamisole in resectable lung cancer.
Amery WK; Cosemans J; Gooszen HC; Lopes Cardozo E; Louwagie A; Stam J; Swierenga J; Vanderschueren RG; Veldhuizen RW
Recent Results Cancer Res; 1978; 68():268-77. PubMed ID: 379936
[TBL] [Abstract][Full Text] [Related]
38. BCG prophylaxis in bladder cancer produces activation of recruited neutrophils.
Vita F; Siracusano S; Abbate R; Ciciliato S; Borelli V; Soranzo MR; Zabucchi G
Can J Urol; 2011 Feb; 18(1):5517-23. PubMed ID: 21333042
[TBL] [Abstract][Full Text] [Related]
39. Monocyte chemotaxis and effect of levamisole in Hodgkin's disease.
Lukács K; Frendl G; Berényi E; Kávai M; Szabó G; Szegedi G
Acta Med Acad Sci Hung; 1980; 37(2):145-50. PubMed ID: 7457021
[TBL] [Abstract][Full Text] [Related]
40. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
